ACIP关于Moderna COVID-19疫苗的临时推荐——美国,2020年12月
2020年12月18日FDA对Moderna COVID-19疫苗(mRNA-1273)颁发紧急使用授权,该疫苗为2剂次(100 μg,0.5 mL each)肌内注射,间隔1个月。12月19日ACIP基于EtR框架和GRADE方法发布临时推荐,建议≥18岁人群使用该疫苗预防COVID-19,并与ACIP初始分配建议配合实施。
要点
- Moderna COVID-19疫苗为2剂次(100 μg,0.5 mL each)肌内注射,间隔1个月(4周)。
- ACIP临时推荐用于≥18岁人群预防COVID-19。
- 所有EUA下COVID-19疫苗的使用应与ACIP初始供应分配建议结合实施。
核心结论
- ACIP临时推荐Moderna COVID-19疫苗用于≥18岁人群预防COVID-19。
研究设计与样本
- ACIP采用Evidence to Recommendation(EtR)框架,使用GRADE方法进行审议。
主要发现
- Moderna COVID-19疫苗为脂质纳米颗粒包裹的核苷修饰mRNA疫苗,编码SARS-CoV-2稳定融合前刺突糖蛋白。
- 该疫苗是美国第二个获得EUA的COVID-19疫苗。
- 接种方案为2剂次(100 μg,0.5 mL each)肌内注射,间隔1个月(4周)。
关键数值与推荐
- 推荐人群:≥18岁。
- 接种剂次与剂量:2剂,每剂100 μg(0.5 mL),肌内注射,间隔1个月(4周)。
临床怎么用
- 在EUA下使用Moderna COVID-19疫苗时,应与ACIP关于初始COVID-19疫苗供应分配的建议结合实施。
- 该ACIP推荐为临时性,将随新信息更新。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Moderna COVID-19 (mRNA-1273) vaccine (ModernaTX, Inc; Cambridge, Massachusetts), a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1). This vaccine is the second COVID-19 vaccine authorized under an EUA for the prevention of COVID-19 in the United States (2). Vaccination with the Moderna COVID-19 vaccine consists of 2 doses (100 μg, 0.5 mL each) administered intramuscularly, 1 month (4 weeks) apart. On December 19, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation* for use of the Moderna COVID-19 vaccine in persons aged ≥18 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP employed the Evidence to Recommendation (EtR) Framework,† using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.§ Use of all COVID-19 vaccines authorized under an EUA, including the Moderna COVID-19 vaccine, should be implemented in conjunction with ACIP's interim recommendations for allocating initial supplies of COVID-19 vaccines (3). The ACIP recommendation for the use of the Moderna COVID-19 vaccine under EUA is interim and will be updated as additional information becomes available.
引用
- Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33382675. doi:10.15585/mmwr.mm695152e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。